close
Add to watchlist
ARYx Therapeutics Inc (ARYX)
ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates designed to eliminate known safety issues associated with commercial drugs using its RetroMetabolic Drug Design technology. Its product portfolio includes tecarfarin, an oral anticoagulant in Phase II/III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; budiodarone/ATI-2042, an oral antiarrhythmic agent in Phase II clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat; ATI-7505, an oral prokinetic agent in Phase II clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. The company also involves in the preclinical development of ATI-20,000 and ATI-24,000, which focus on metabolic and gastrointestinal disorders. ARYx Therapeutics, Inc. was incorporated in 1997 and is based in Fremont, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 9999.99 |
| Volume | 607611 |
| Volume Avg | (mio) 1058.64 |
| 52 Week High | 0.03 |
| 52 Week Low | 0.00 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | 0.00 |
| EPS change Q/Q | -27.27% |
| EPS change Q/Q Yr ago | -73.33% |
| EPS change Q/Q next Q est | 100% |
| EPS change Y/Y | -153.23% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |